Vimta Labs Ltd

Vimta Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vimta Labs Ltd

₹ 450 -2.21%
15 May - close price
vimta.com BSE: 524394 NSE: VIMTALABS
About

Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider[1]

Key Points

Business Overview:[1]
VLL is is in the business of contract research and testing in the fields of biologics, small molecules, agro -chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing

Website BSE NSE
  • Market Cap ₹ 2,012 Cr.
  • Current Price ₹ 450
  • High / Low ₹ 903 / 376
  • Stock P/E 25.6
  • Book Value ₹ 102
  • Dividend Yield 0.44 %
  • ROCE 25.2 %
  • ROE 18.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 29.9% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
81 82 64 73 73 75 85 90 94 98 102 99 109
57 58 48 50 47 49 55 57 61 64 68 64 70
Operating Profit 24 24 17 23 26 26 30 33 33 34 34 34 39
OPM % 29% 29% 26% 31% 36% 35% 35% 37% 35% 35% 34% 35% 36%
1 1 0 -1 -1 -1 -1 5 2 2 3 0 3
Interest 0 0 1 1 1 0 0 1 0 0 0 0 0
Depreciation 8 8 9 8 8 8 8 10 9 10 10 11 13
Profit before tax 16 16 8 13 16 17 20 28 25 25 26 23 29
Tax % 23% 25% 25% 25% 24% 26% 24% 23% 27% 25% 24% 25% 27%
12 12 6 9 12 12 15 22 18 19 20 18 21
EPS in Rs 2.77 2.63 1.34 2.14 2.79 2.77 3.44 4.84 4.12 4.24 4.47 3.94 4.73
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
116 138 154 183 213 181 209 276 315 289 344 407
99 119 127 138 155 151 156 196 222 195 222 266
Operating Profit 17 19 27 45 58 30 53 80 94 94 122 142
OPM % 15% 14% 18% 25% 27% 17% 25% 29% 30% 33% 35% 35%
1 1 1 1 2 3 1 0 3 -4 5 7
Interest 1 1 2 5 5 4 2 2 3 2 2 1
Depreciation 11 10 10 16 20 21 23 23 31 33 35 44
Profit before tax 7 8 17 26 35 8 28 55 64 55 90 104
Tax % 24% 23% 36% 36% 28% 17% 25% 26% 26% 25% 25% 25%
5 6 11 16 25 7 21 41 47 41 67 78
EPS in Rs 1.14 1.45 2.40 3.72 5.73 1.57 4.81 9.29 10.68 9.26 15.13 17.35
Dividend Payout % 44% 34% 0% 27% 17% 0% 21% 11% 9% 11% 7% 12%
Compounded Sales Growth
10 Years: 11%
5 Years: 14%
3 Years: 9%
TTM: 18%
Compounded Profit Growth
10 Years: 29%
5 Years: 30%
3 Years: 19%
TTM: 17%
Stock Price CAGR
10 Years: 28%
5 Years: 32%
3 Years: 34%
1 Year: -13%
Return on Equity
10 Years: 15%
5 Years: 18%
3 Years: 18%
Last Year: 19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 4 4 4 4 4 4 4 4 4 4 4 9
Reserves 118 122 132 148 167 169 190 229 276 310 374 448
4 26 44 40 26 32 30 19 15 19 9 3
21 23 42 40 40 39 49 54 65 61 79 102
Total Liabilities 146 176 222 232 237 245 273 306 360 394 467 562
88 88 88 140 135 131 128 162 168 166 230 305
CWIP 0 6 53 0 4 2 17 0 12 59 38 18
Investments 0 0 0 0 0 6 6 6 6 0 0 2
58 82 80 92 99 105 122 138 174 170 198 237
Total Assets 146 176 222 232 237 245 273 306 360 394 467 562

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
15 -1 24 33 39 24 37 59 87 61 95 147
-8 -16 -39 -24 -16 -20 -32 -38 -57 -76 -76 -130
-9 19 13 -8 -23 -1 -5 -16 -11 -2 -17 -10
Net Cash Flow -1 2 -2 1 1 3 1 5 19 -17 2 7
Free Cash Flow 8 -17 -16 9 23 10 5 20 37 -14 18 47
CFO/OP 96% 4% 107% 86% 85% 101% 84% 94% 106% 81% 96% 121%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 82 100 101 111 100 117 128 102 93 110 113 95
Inventory Days 158 213 183 209 199 191 140 154 195 260 210 136
Days Payable 66 77 184 148 115 114 139 108 124 87 88 53
Cash Conversion Cycle 174 236 100 172 184 194 128 147 164 283 235 177
Working Capital Days 109 99 22 62 78 64 89 87 78 98 96 84
ROCE % 6% 7% 11% 17% 21% 6% 14% 24% 24% 20% 25% 25%

Insights

In beta
Mar 2006 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Number of Employees
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Laboratories
Number
Laboratory Space Area
Sq. Ft.
Regulatory Audits (International)
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
37.23% 37.00% 36.98% 36.92% 36.89% 36.89% 36.76% 36.70% 36.67% 35.99% 35.89% 35.85%
2.72% 2.74% 2.88% 5.13% 5.16% 3.31% 3.81% 3.66% 3.49% 4.33% 4.59% 4.89%
2.14% 1.50% 1.49% 1.50% 1.49% 0.00% 1.15% 1.43% 1.42% 0.87% 0.11% 0.13%
57.92% 58.75% 58.65% 56.45% 56.45% 59.80% 58.28% 58.20% 58.42% 58.80% 59.40% 59.12%
No. of Shareholders 17,43918,42919,95718,55019,05420,11421,15626,18330,82955,93354,46751,623

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls